Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | General Counsel & COO | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PMV Pharmaceuticals, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2035-03-05 | Direct | 319,270 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 319,270 · Balance 319,270 F1: Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 9, 2026 16:39 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 319,270 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001613482-26-000002 · form4-03092026_080354.xml · derivative · entry 1 Ticktin Robert · CIK 0001613482 · General Counsel & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,270 Underlying: Common Stock · 319,270 shares Expires 2035-03-05 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2026. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:51 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 23,151 | $1.06 | $24,651.18 |
DisclosureSEC source: 0001415889-25-019386 · form4-07032025_110750.xml · nonDerivative · entry 1 Ticktin Robert · CIK 0001613482 · General Counsel & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,695 F1 · shares: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · balance_after: Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.